Advanced Synthetic Biology For Planet and Human Health
CB Therapeutics is leading the synthetic biology revolution for producing next-generation research molecules and animal-free ingredients. We create sustainable, innovative bio-manufacturing solutions to supply diverse industries from clinical research and nutraceuticals, to cosmetics and the food and beverage markets.
Our Production Capacity
CB Therapeutics is trailblazing the creation of new opportunities for therapeutic solutions involving:
Groundbreaking Science Powered by Yeast.
We use a cutting-edge proprietary yeast platform that enhances natural metabolic processes through precision fermentation to produce a variety of compounds, from small chemical analogs to bio-identical molecules that exactly match their counterparts in nature. The advantage of our approach is that it delivers pure, consistent, and reliable molecules.
In the News.
May 19, 2022
To tackle sustainable food and active ingredient manufacturing, CB Therapeutics is developing eco-conscious solutions through precision fermentation
CARLSBAD, Calif., July 21, 2022 — CB Therapeutics (the "Company"), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, has successfully developed various food tech prototypes using its next-gen synbio and precision fermentation platform. Now, the Company is looking for partnerships in the food technology and active ingredient spaces that align with its value propositions.
May 19, 2022
CB Therapeutics’ Business Development Lead, Tiffany Hurd, is Further Bridging the Gap Between Pharma and Psychedelics
CARLSBAD, Calif., June 20, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the "Company"), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, welcomes a new member of the team who is focused on growth and sustainability.
April 25, 2022
CB Therapeutics rapidly expands cellular agriculture capabilities at new facility
CARLSBAD, Calif., April 25, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the “Company”), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, is celebrating a move to an expanded laboratory, which will serve to
increase its research compound production footprint.
December 20, 2021
Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) — CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board.
December 9, 2021
CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) — CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase healthspan, believes their partnership with atai Life Sciences will help to meet the growing unmet needs of patients with mental health conditions.
August 24, 2021
CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is happy to announce that it has been awarded two more patents for the novel methods of production of high value molecules using cutting-edge biosynthesis technologies. These patents (11,041,002B1 and 10,988,785B1) cover inventions on cellular agriculture breakthroughs for producing cannabinoids and precursors to various other compounds…
May 10, 2021
CB Therapeutics Closes on Oversubscribed Series A
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., the leading synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, is pleased to announce that it has closed an oversubscribed Series A funding round, filled entirely by re.Mind Capital, a fund launched by the psychedelics kingmaker, Christian Angermayer within Apeiron, his family office…
September 23, 2020
CB Therapeutics Achieves Major Breakthroughs in Downstream Processing and Purification, Paving the Way for Low-cost Cannabinoids, Tryptamines, and Their Analogs
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., has successfully refined its in-house downstream processing, allowing for 99.6% pure CBC. a rare cannabinoid molecule found in trace quantities in cannabis and hemp. Using these patent-pending techniques, CB Therapeutics is able to drive down the cost of purification in parallel with increasing the purity to over 99%, considered a major breakthrough for any type of purification process…
Our Blog.
